Wall Street analyst estimates for Actuate Therapeutics Inc (ACTU): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.18 | ||
| 2026-08-14 | $-0.20 | $-0.20 | +1.6% |
| 2026-05-14 | $-0.24 | $-0.23 | -4.3% |
| 2026-03-26 | $-0.18 | $-0.24 | +25.0% |
| 2025-11-13 | $-0.25 | $-0.27 | +7.4% |
| 2025-08-14 | $-0.30 | $-0.19 | -57.9% |
| 2025-05-15 | $-0.32 | $-0.30 | -6.7% |
| 2025-03-13 | $-0.33 | $-0.29 | -13.8% |
Valuation Ratios
| Price / Book | 27.40 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Research & Development | $16.4M | $21.7M | $18.7M | $10.3M |
| Selling, General & Admin | $3.8M | $3.3M | $6.5M | $12.2M |
| Operating Expenses | $20.2M | $25.0M | $25.2M | $22.5M |
| Operating Income | -$20.2M | -$25.0M | -$25.2M | -$22.5M |
| EBITDA | -$20.1M | -$24.4M | -$25.2M | -$22.2M |
| Interest Expense | $16200 | $43641 | -$18717 | $20250 |
| Pre-tax Income | -$20.2M | -$24.7M | -$27.3M | -$22.2M |
| Income Tax | 0 | 0 | $800 | 0 |
| Net Income | -$20.2M | -$24.7M | -$27.3M | -$22.2M |
| EPS | $-1.34 | $-1.65 | $-3.26 | $-1.06 |
| EPS (Diluted) | $-1.34 | $-1.65 | $-3.26 | $-1.06 |
| Shares Outstanding (Diluted) | $15.0M | $15.0M | $19.5M | $21.0M |
Price
| Price | $1.00 |
| Market Cap | $24M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALEC · APLT · ELTX · MCRB · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of ACTU: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks